867256-73-3

Basic information

• Product Name: (R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine
• Synonyms: (R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine
• CAS NO: 867256-73-3
• Molecular Formula: C₁₀H₂₀N₂
• Molecular Weight: 168.2792
• Mol File: 867256-73-3.mol

Chemical Properties

• Boiling Point: 228.1°C at 760 mmHg
• Flash Point: 80.7°C
• Appearance: /
• Density: 0.944g/cm3
• Vapor Pressure: 0.0749mmHg at 25°C
• Refractive Index: 1.486
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine(867256-73-3)
• EPA Substance Registry System: (R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine(867256-73-3)

Safety Data

• Hazardous Substances Data: 867256-73-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine is used as a building block in organic synthesis for constructing complex molecules. Its unique structure and chirality make it a valuable component in the synthesis of pharmaceuticals and other organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine is used as a precursor for the development of new drugs. Its potential biological activity and chiral nature are being studied for their applications in creating novel therapeutic agents.
Used in Asymmetric Synthesis:
(R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine is utilized as a chiral auxiliary in asymmetric synthesis, where it aids in the selective formation of one enantiomer over another. This is crucial in the production of enantiomerically pure compounds, which is often necessary for biological activity and pharmaceutical applications.
Used in Stereoselective Reactions:
(R)-2-methyl-1-((S)-pyrrolidin-2-ylmethyl)pyrrolidine is also employed in stereoselective reactions, where it helps to control the stereochemistry of the products formed. This is particularly important in the synthesis of biologically active molecules, where stereochemistry can significantly influence the molecule's activity and efficacy.

InChI:InChI=1/C10H20N2/c1-9-4-3-7-12(9)8-10-5-2-6-11-10/h9-11H,2-8H2,1H3

Upstream product

• 1379448-37-9 (2(R)-methyl-pyrrolidin-1-yl)-pyrrolidin-2-yl-methanone 

Downstream Products

• 867256-82-4 [2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanone 

Relevant articles and documents

NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In anot

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES

The present invention provides novel compounds with histamine-H3 receptor antagonist or inverse agonist activity. In particular, the invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions com

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases